Pieris Pharmaceuticals Inc.
Pieris AG is a clinical-stage biopharmaceutical company dedicated to the discovery and development of its proprietary Anticalin® class of biotherapeutics. The company has successfully developed a clinical-stage pipeline and closed commercial collaboration with firms like Daiichi Sankyo, Sanofi Pasteur and Allergan.
Pieris AG completed a share exchange transaction with Pieris Pharmaceuticals, Inc. (OTC:PIRS) (formerly Marika, Inc.), pursuant to which Pieris AG became a wholly-owned subsidiary of the Company. The combined entity is named Pieris Pharmaceuticals, Inc and began trading under the symbol “PIRS” on the OTC Markets on December 18, 2014.
Pieris is located in the Munich area (Germany).